Kane Biotech Inc KNBIF

New Press Release - Kane Biotech Makes First Commercial Sale of revyve(TM) Antimicrobial Wound Gel to ProgenaCare Global

Kane Also Signs Long-Term Manufacturing Agreement With Halo Pharma WINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of revyve™ Antimicrobial Wound Gel product...read article.

[RoyMax123]

at one minute to midnight, finally the full production.

[francoisl13]

Yup, and, for once, they've met their promises in regards to timing so, this is refreshing and very encouraging for the future. GLTA

[KevinOleary]

The timelines for dispersin trials are determined 100% by the FDA. kne just tried to estimate when the trials would start, but it's a mug's game. The FDA is a massive bureaucracy, and doesn't know much about biofilms. The pre-application meetings are widely spaced apart and you don't get to talk to people who will give you a nice blueprint of how to submit an application for

[RoyMax123]

They should change their name from Kane to Pfyzer, maybe that would fool the FDA to go faster ;-)

[KevinOleary]

FDA marches to their own drum, and could care less who applies, otherwise small biotechs would be at the mercy of big ones because they would have to make deals with them to get the fast approval.

[francoisl13]

The news we were waiting for...on-time...excellent! Now we can start looking at sales increase over time, new Revyve products intorduction, new distribution partnership for Europe, Australia, etc... Not talking about DispersinB....yet :) GLTA